AI-powered imaging startup AIRS Medical raises $20M Series B

AIRS Medical, a South Korea-based healthcare startup, today announced that it has raised approximately $20 million in a Series B funding round.

New investors Q Capital Partners and Hanwha Life joined the round, which also included participation from Klim Ventures, which contributed to AIRS Medical’s Series A round.

AIRS Medical, which was co-founded by Seoul National University graduates in 2018, develops AI-based digitized diagnostic tests and robotic technologies aimed at providing a better clinical experience for patients and healthcare providers. health, according to a press release.

Artificial intelligence (AI)-powered magnetic resonance imaging (MRI) reconstruction software SwiftMR has been developed and commercialized, the company said. AIRS Medical designed the platform to enhance MRI images acquired under various conditions to provide a higher level of data accuracy and a better patient experience.

SwiftMR has obtained approval from the FDA and Korea’s Ministry of Food and Drug Safety (MFDS) since last year. The platform is now being introduced beyond Korea in the United States, Europe, Southeast Asia and South America, having also won the fastMRI 2019 and 2020 challenge co-hosted by Facebook AI Research (FAIR ) and NYU Langone Health.

Earlier this year, the company acquired artiQ, an AI and robotics-based startup that shares its vision, successfully adding in vitro diagnostics to AIRS Medical’s technology portfolio, which also includes puncture automation. venous. The company said that in the future, it plans to use its technology and clinical expertise to introduce consecutive diagnostic testing solutions that “break new ground in the cost structure of the medical industry.”

“We believe we can transform the healthcare ecosystem by solving the current reliance on analog machines by replacing them with data-driven medicine,” said Hye-seong Lee, CEO of AIRS Medical, in the press release. hurry. He continued, “With the Series B funding we have secured, we will bring our innovative diagnostic solutions to the global market.